Skip to main content
OpenTrials

Clinical trial condition

Communicable Diseases

Explore clinical trials studying Communicable Diseases. Study availability and eligibility vary by location and protocol.

9,170 public trials 550 recruiting studies
Refine in advanced search Browse all conditions

Communicable Diseases trial results

Completed

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

NCT01825031

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • Moi University Clinical Research Centre Eldoret, Kenya
  • KEMRI Wellcome Trust Research Programme Kilifi, Kenya
  • University of Malawi Blantyre, Malawi
  • Joint Clinical Research Centre, Fort Portal Fort Portal, Uganda
View Trial Details
Completed

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

NCT01970904

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Cologne, Germany
  • Novartis Investigative Site Düsseldorf, Germany
View all 25 locations
View Trial Details
Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

NCT00905632

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.7.3307A CHU de Grenoble Grenoble Cédex 9, France
  • 1241.7.3303A Hôpital Claude Huriez Lille, France
  • 1241.7.3302A Hopital de l'Hotel Dieu Lyon, France
  • 1241.7.3301A Hôpital Saint Eloi Montpellier, France
View all 18 locations
View Trial Details
Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

NCT01732796

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.20.00026 Boehringer Ingelheim Investigational Site Dothan, Alabama, United States
  • 1241.20.00033 Boehringer Ingelheim Investigational Site Chula Vista, California, United States
  • 1241.20.00006 Boehringer Ingelheim Investigational Site La Mesa, California, United States
  • 1241.20.00003 Boehringer Ingelheim Investigational Site Oceanside, California, United States
View all 101 locations
View Trial Details
Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • La Jolla, California, United States
  • Long Beach, California, United States
  • San Diego, California, United States
  • San Diego, California, United States
View all 25 locations
View Trial Details

Related conditions